Delayed Inflammatory Reaction to Hyaluronic Acid Dermal Filler Following Zoledronic Acid Administration: A Case Report
DOI: https://doi.org/10.2147/ccid.s458750
2024-06-11
Clinical Cosmetic and Investigational Dermatology
Abstract:Nada J Alghamdi, 1, &ast Serene R Almuhaidib, 2, &ast Abdulmajeed S Alharbi, 2, &ast Abdullah Ali N Aljalfan, 1, &ast Khalid M Al-Husain 1 1 Department of Dermatology, King Fahd University Hospital, Al Khobar, Saudi Arabia; 2 College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia &astThese authors contributed equally to this work Correspondence: Abdullah Ali N Aljalfan, Department of Dermatology, King Fahd University Hospital, P.O. Box 34246, Al Khobar, Saudi Arabia, Email Zoledronic acid is a bisphosphonate that can be administered intravenously and used to treat several bone disorders. It decreases bone resorption, thereby improving bone mineral density (BMD) and reducing fractures. The Food and Drug Administration (FDA) has approved zoledronic acid for the prevention and treatment of osteoporosis in postmenopausal females and males and for other conditions. Zoledronic acid is generally well tolerated, with most side effects being musculoskeletal or gastrointestinal. Cutaneous side effects include maculopapular rash and other mild skin reactions. Rare severe skin rashes, such as toxic epidermal necrolysis, have been reported. Here, we report the case of a 64-year-old female with a medical history of breast cancer status post-radical mastectomy and chemotherapy presenting with delayed hypersensitivity reaction to a hyaluronic acid dermal filler two days after receiving zoledronic acid intravenously given to maintain bone density, symptoms completely resolved with oral prednisolone 20 mg once daily and cetirizine 10 mg. Cases of delayed inflammatory reaction to hyaluronic acid soft tissue filler have previously been reported in patients who have received vaccination or those with viral infections. However, to our knowledge, there have been no reports of delayed inflammatory reactions to facial hyaluronic acid injections after zoledronic acid administration. Keywords: delayed inflammation, filler, zoledronic acid, hyaluronic acid Zoledronic acid (ZA) is an intravenous bisphosphonate used to treat several benign and malignant bone disorders. It is mainly used for the treatment of primary and secondary osteoporosis. Zoledronic acid decreases bone resorption by increasing osteoclast apoptosis. 1 The most common side effects of zoledronic acid are musculoskeletal pain, gastrointestinal symptoms, conjunctivitis, and nephrotoxicity, and, to a lesser extent, atypical fractures and jaw osteonecrosis. 2 Rarely, cutaneous side effects can occur, and are mostly mild and self-limiting. These include maculopapular rashes, dermatitis, figurate erythema, erythema multiforme, vasculitis, and lip ulceration. Nonetheless, severe cutaneous adverse events such as toxic epidermal necrolysis may occur. 3,4 Hyaluronic acid soft tissue fillers are non-permanent and non-invasive aesthetic procedure. They have become one of the most prevalent non-surgical treatments due to their excellent safety profile and delivering significant results in facial rejuvenation and high patient satisfaction. Immune reactions to hyaluronic acid dermal fillers are rare and can be early-onset or late-onset. 5 To the best of our knowledge, this is the first report of a hypersensitivity reaction to a hyaluronic acid dermal filler following the administration of zoledronic acid to a 64-year-old female patient. A 64-year-old female presented to the outpatient clinic of our hospital with a two-day history of localized and progressively increasing firm swelling on her face in the jaw and cheeks at sites of previously injected fillers (Figure 1). There was no pain, erythema, itchiness, shortness of breath, visible erythema, or other systemic involvement. Two days prior to onset, she received her first-ever dose of zoledronic acid 5 mg intravenously. A further history of the patient ruled out any previous allergies or angioedema, and she had not been taking any medications and had no recent viral illness, dental or other potential bacterial infections, recent vaccination, or history of trauma. One year later, she was injected with 1 mL of hyaluronic acid filler Juvederm Voluma into the lateral cheek and 1 mL of Juvéderm VOLUX into the chin area with good results and no subsequent complications. Figure 1 ( A and B ) Induration and edema at sites of dermal filler injection most prominent in the lateral cheek area. Her medical history was significant for stage three breast cancer status after left radical mastectomy nine years ago, followed by chemotherapy and trastuzumab therapy for one year. She is currently receiving tamoxifen 10 mg once daily. The oncologist advised her to administer zoledronic acid to -Abstract Truncated-
dermatology